51漫画app

Facing a rare or severe disease can be overwhelming, especially when access to lifesaving cell and gene therapies (CGTs) is limited.  

CGTs offer new hope for people with rare and severe diseases by modifying or replacing cells or genes to treat conditions once thought untreatable. While CGTs hold tremendous promise, the path to treatment is full of potential obstacles along the way.  

These personalized therapies require precise handling and careful management to remain viable. Patients must uproot their lives, traveling to highly specialized centers for infusion and weeks of intensive monitoring. These are just a few of the difficulties that can prevent patients from accessing care.  

That’s why InspiroGene™ by McKesson launched the InspiroCare™ Patient Hub (InspiroCare) to guide patients through every step of their treatment journey and provide personalized support.

Keeping Patients on the Path to Treatment  

InspiroGene by 51漫画appset out to develop a patient support service that addresses the financial and logistical challenges of cell and gene therapy, helping to ensure people can receive the life-saving treatment they need. 

“Patients are often dealing with complex cancers, such as multiple myeloma, where they have only months or years to live,” said Jonathon DiTroia, vice president of product strategy at InspiroGene by McKesson. “Or, they are children with rare diseases who have life expectancies in single-digit years. These therapies are often their only or last option.” 

Drawing on deep clinical expertise and decades of experience in patient support, InspiroCare was designed to identify key barriers and deliver tailored services that keep patients on track for treatment. Supported by the specialty pharmacy expertise of Biologics by McKesson, InspiroCare connects biopharma companies, commercialization partners, payers and providers through a holistic support system for CGTs.

How InspiroCare Supports Patients Every Step of the Way

What is the InspiroCare Patient Hub? 

The InspiroCare^TM Patient Hub (InspiroCare) is a technology-driven support service from InspiroGene by McKesson, designed to guide patients through every step of their cell and gene therapy journey. 

Powered by an integrated operating model and advanced digital platform, InspiroCare streamlines coordination among patients, providers and biopharma partners — delivering real-time visibility, efficient workflow integration and simplified access to advanced therapies.  

Patients and caregivers have access to clinical experts, receiving personalized and compassionate guidance that serves as a lifeline during uncertain or overwhelming times. 

How does InspiroCare support patients? 

Each patient is matched with a case manager, ensuring personalized, high-touch support throughout their treatment journey. 

“We act as air traffic control,” said Stephanie Patten, vice president of rare disease and advanced therapies at Biologics by McKesson. “InspiroCare makes sure the product, the patient and the provider all land at the treatment center at the right time. We’re part of the journey from referral, reimbursement navigation and logistics through post-treatment follow-up, making sure everything is lined up perfectly to get the patient their life-changing therapy.” 

What services does InspiroCare offer? 

InspiroCare offers services designed to support patients and healthcare providers throughout the treatment process. These services include: 

• Arranging travel and lodging 
• Enrolling patients in assistance or copay programs  
• Providing personalized support and coordinating care to ensure patients remain eligible and receive timely treatment. 

InspiroCare’s flexible service model enables biopharma partners to select and scale support options to fit their needs, ensuring seamless coordination and transparency throughout the patient journey. 

Why is this approach critical now? 

With more than 40 cell and gene therapies approved and new treatments expanding into larger disease areas, InspiroCare is ready to meet growing demand with scalable, adaptable and patient-centered solutions. 

“This is a pivotal moment in the trajectory of cell and gene therapy,” said Patten. “We are proud to support the advancement of cell and gene therapies through our purpose-built hub programs.”